Cumberland Pharmaceuticals Inc (CPIX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Cumberland Pharmaceuticals Inc (CPIX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014391
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cumberland Pharmaceuticals Inc (Cumberland Pharma) is a pharmaceutical company which develops and commercializes branded prescription products. The company’s product portfolio includes acetylcysteine, ibuprofen, lactulose, conivaptan, amifostine and ifetroban. It provides prescription products for hospitals, acute cares, unmet medical needs and gastroenterology. Cumberland Pharma’s acetylcysteine is used for the prevention of liver damage resulting from acetaminophen overdose. The company works in partnership Phebra Pty Ltd, Teligent Pharmaceuticals Inc, DB Pharm Korea Co Ltd, Sandor Medicaids Pvt. Ltd for commercialization of the products internationally. It markets the branded products through a channel of network distributors in the US and abroad. Cumberland Pharma is headquartered in Nashville, Tennessee, the US.

Cumberland Pharmaceuticals Inc (CPIX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 13
Cumberland Pharma Acquires Rights Of Ifetroban From Vanderbilt University 15
Partnerships 17
Cumberland Pharma and Poly Pharma Enter into Co-promotion Agreement 17
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 18
Cumberland Pharma Enters into Agreement with Piramal Critical Care 19
Cumberland Pharma Enters into Agreement with Clinigen 20
Cumberland And Harbin Gloria Enter Into R&D Agreement With Cumberland Emerging 21
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 22
Cumberland Emerging Technologies Enters Into Agreement With Washington University in St. Louis 23
Licensing Agreements 24
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 24
Cumberland Pharma Enters into Licensing Agreement with Nordic Group 25
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 26
Cumberland Pharma Enters Into Licensing Agreement With Sandor Medicaids For Caldolor 27
Cumberland Pharma Enters Into Licensing Agreement With SOHO Industri Pharmasi For Caldolor 28
Harbin Gloria Pharma Enters Into Licensing Agreement With Cumberland Pharma For Acetadote and Caldolor 29
Equity Offering 30
Cumberland Pharma Plans to Raise up to USD25 Million in Public Offering of Shares 30
Cumberland Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 31
Cumberland Pharmaceuticals Inc – Key Competitors 32
Cumberland Pharmaceuticals Inc – Key Employees 33
Cumberland Pharmaceuticals Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Nov 07, 2017: Cumberland Pharmaceutical Reports 27% Revenue Growth In The Third Quarter 35
Aug 08, 2017: Cumberland Pharmaceuticals Reports Double Digit Revenue Growth for the Fourth Consecutive Quarter 37
May 15, 2017: Cumberland Pharmaceuticals Reports Revenue Growth Of 25% In First Quarter 2017 39
Mar 07, 2017: Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results 41
Nov 01, 2016: Cumberland Pharmaceuticals Reports Third Quarter & Year To Date 2016 Financial Results 43
Aug 02, 2016: Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results 45
May 10, 2016: Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results 47
Mar 03, 2016: Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results 49
Corporate Communications 50
Jan 16, 2017: Cumberland Pharmaceuticals Announces Kenneth J. Krogulski To Join Its Board Of Directors 50
Jun 10, 2016: Cumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors 51
Product Approvals 52
Apr 27, 2016: Cumberland Pharmaceuticals Announces New Program To Develop Vasculan For Systemic Sclerosis 52
Clinical Trials 53
Sep 14, 2016: Cumberland Pharmaceuticals Announces New Program To Develop Portaban For Portal Hypertension 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cumberland Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Cumberland Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cumberland Pharma Acquires Vaprisol From Astellas Pharma 13
Cumberland Pharma Acquires Rights Of Ifetroban From Vanderbilt University 15
Cumberland Pharma and Poly Pharma Enter into Co-promotion Agreement 17
Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 18
Cumberland Pharma Enters into Agreement with Piramal Critical Care 19
Cumberland Pharma Enters into Agreement with Clinigen 20
Cumberland And Harbin Gloria Enter Into R&D Agreement With Cumberland Emerging 21
Cumberland Pharma Enters Into Co-Promotion Agreement With Pernix Therapeutics 22
Cumberland Emerging Technologies Enters Into Agreement With Washington University in St. Louis 23
Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 24
Cumberland Pharma Enters into Licensing Agreement with Nordic Group 25
Grifols Enters Into Licensing Agreement With Cumberland Pharma For Caldolor 26
Cumberland Pharma Enters Into Licensing Agreement With Sandor Medicaids For Caldolor 27
Cumberland Pharma Enters Into Licensing Agreement With SOHO Industri Pharmasi For Caldolor 28
Harbin Gloria Pharma Enters Into Licensing Agreement With Cumberland Pharma For Acetadote and Caldolor 29
Cumberland Pharma Plans to Raise up to USD25 Million in Public Offering of Shares 30
Cumberland Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 31
Cumberland Pharmaceuticals Inc, Key Competitors 32
Cumberland Pharmaceuticals Inc, Key Employees 33
Cumberland Pharmaceuticals Inc, Subsidiaries 34

★海外企業調査レポート[Cumberland Pharmaceuticals Inc (CPIX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Infinite Group Inc (IMCI):企業の財務・戦略的SWOT分析
    Summary Infinite Group Inc (IGI) is a technology company that offers IT service and support solutions virtualization and cybersecurity. The company offers Nodeware, an automated network vulnerability management system that assesses vulnerabilities in a computer network using scanning technology. Its …
  • Eurocommercial Properties NV:企業の戦略・SWOT・財務分析
    Eurocommercial Properties NV - Strategy, SWOT and Corporate Finance Report Summary Eurocommercial Properties NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • PTC, Inc. (PTC):企業の財務・戦略的SWOT分析
    PTC, Inc. (PTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Stanford University:企業のM&A・事業提携・投資動向
    Stanford University - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stanford University Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Sears Holdings Corporation (SHLD):企業の財務・戦略的SWOT分析
    Sears Holdings Corporation (SHLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • AnGes Inc (4563):医療機器:M&Aディール及び事業提携情報
    Summary AnGes Inc (AnGes) is a biopharmaceutical company which discovers and develops gene and nucleotide based drugs and reagents for use in functional analysis of genetic medication. The company specializes in research and development (R&D) and practical application of genetic medicine. It has two …
  • Royal BAM Group nv:戦略・SWOT・企業財務分析
    Royal BAM Group nv - Strategy, SWOT and Corporate Finance Report Summary Royal BAM Group nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Abzena Plc (ABZA):製薬・医療:M&Aディール及び事業提携情報
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include …
  • The Nature’s Bounty Co:企業の戦略的SWOT分析
    The Nature's Bounty Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • bet-at-home.com AG (ACX):企業の財務・戦略的SWOT分析
    bet-at-home.com AG (ACX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Amneal Pharmaceuticals Inc:企業のM&A・事業提携・投資動向
    Amneal Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Amneal Pharmaceuticals Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Xspray Pharma AB (XSPRAY):製薬・医療:M&Aディール及び事業提携情報
    Summary Xspray Pharma AB (Xspray Pharma), formerly Xspray Microparticles AB, is a drug development company that develops and commercializes protein kinase inhibitors (PKI) for targeted cancer treatments. The company’s drug candidates include HyNap-Dasa, HyNap-Nilo and HyNap-Sora. Its protein kinase …
  • Lagardere SCA:企業のM&A・事業提携・投資動向
    Lagardere SCA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lagardere SCA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • STMicroelectronics NV (STM):企業の財務・戦略的SWOT分析
    STMicroelectronics NV (STM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • GE Energy Power Conversion Group:企業の戦略的SWOT分析
    GE Energy Power Conversion Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • L Brands Inc:戦略・SWOT・企業財務分析
    L Brands Inc - Strategy, SWOT and Corporate Finance Report Summary L Brands Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Msc Industrial Direct Co., Inc.
    Msc Industrial Direct Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Msc Industrial Direct Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • ProMetic Life Sciences Inc (PLI):製薬・医療:M&Aディール及び事業提携情報
    Summary ProMetic Life Sciences Inc (ProMetic) is a biopharmaceutical company that focuses on bioseparations, plasma-derived therapeutics and small-molecule drug development. The company develop products for the treatment for fibrosis, anemia, autoimmune diseases, inflammation and nephropathies. The …
  • Singapore Technologies Electronics Ltd:企業の戦略・SWOT・財務情報
    Singapore Technologies Electronics Ltd - Strategy, SWOT and Corporate Finance Report Summary Singapore Technologies Electronics Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Chevron Corporation (CVX)-エネルギー分野:企業M&A・提携分析
    Summary Chevron Corporation (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for produces and transports cr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆